Patient groups are calling for a pharmaceutical firm to cut the cost of a bone marrow cancer drug so it can be used by the NHS in England and Wales. Drug advisers the National Institute for Health and Clinical Excellence said lenalidomide was not cost effective for myeloma in a draft ruling.
Link to Article
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment